Edward R Marcantonio1, Kerry Palihnich, Paul Appleton, Roger B Davis. 1. Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA. emarcant@bidmc.harvard.edu
Abstract
OBJECTIVES: To determine whether donepezil hydrochloride can reduce the prevalence and severity of delirium in older adults undergoing hip fracture repair. DESIGN: Pilot double-masked randomized placebo-controlled trial. SETTING: Large academic medical center. PARTICIPANTS: Sixteen individuals aged 70 and older with hip fracture. INTERVENTION: Donepezil 5 mg or placebo was randomly allocated and initiated within 24 hours of surgery, preoperatively or postoperatively. Daily treatment was continued for 30 days or until side effects or the clinical situation required termination. MEASUREMENTS: All outcomes were ascertained masked to treatment status. Information on drug tolerability and safety was obtained from the participant, nurse, and medical record. Delirium presence and severity were measured during daily hospital interviews and at 2, 4, and 6 weeks after surgery after a standardized assessment using the Confusion Assessment Method (CAM) and the Memorial Delirium Assessment Scale (MDAS). RESULTS: Participants in the donepezil and placebo arms had similar baseline characteristics. Participants in the donepezil arm experienced significantly more side effects. In longitudinal models, there were no significant differences between the donepezil and placebo arms with regard to delirium presence over time (odds ratio = 0.9, 95% confidence interval (CI) = 0.4-2.3) or delirium severity over time (effect size = -0.2 on 30-point MDAS scale, 95%CI = -1.5-1.2). CONCLUSION: Participants randomized to donepezil had no significant improvement in delirium presence or severity but experienced more side effects. Overall, sufficient evidence was not found from this pilot study to warrant a definitive Phase III trial.
RCT Entities:
OBJECTIVES: To determine whether donepezil hydrochloride can reduce the prevalence and severity of delirium in older adults undergoing hip fracture repair. DESIGN: Pilot double-masked randomized placebo-controlled trial. SETTING: Large academic medical center. PARTICIPANTS: Sixteen individuals aged 70 and older with hip fracture. INTERVENTION: Donepezil 5 mg or placebo was randomly allocated and initiated within 24 hours of surgery, preoperatively or postoperatively. Daily treatment was continued for 30 days or until side effects or the clinical situation required termination. MEASUREMENTS: All outcomes were ascertained masked to treatment status. Information on drug tolerability and safety was obtained from the participant, nurse, and medical record. Delirium presence and severity were measured during daily hospital interviews and at 2, 4, and 6 weeks after surgery after a standardized assessment using the Confusion Assessment Method (CAM) and the Memorial Delirium Assessment Scale (MDAS). RESULTS:Participants in the donepezil and placebo arms had similar baseline characteristics. Participants in the donepezil arm experienced significantly more side effects. In longitudinal models, there were no significant differences between the donepezil and placebo arms with regard to delirium presence over time (odds ratio = 0.9, 95% confidence interval (CI) = 0.4-2.3) or delirium severity over time (effect size = -0.2 on 30-point MDAS scale, 95%CI = -1.5-1.2). CONCLUSION:Participants randomized to donepezil had no significant improvement in delirium presence or severity but experienced more side effects. Overall, sufficient evidence was not found from this pilot study to warrant a definitive Phase III trial.
Authors: Samuel E Simon; Margaret A Bergmann; Richard N Jones; Katherine M Murphy; E John Orav; Edward R Marcantonio Journal: J Am Med Dir Assoc Date: 2006-05-30 Impact factor: 4.669
Authors: Maarten M J van Eijk; Kit C B Roes; Marina L H Honing; Michael A Kuiper; Attila Karakus; Mathieu van der Jagt; Peter E Spronk; Willem A van Gool; Roos C van der Mast; Jozef Kesecioglu; Arjen J C Slooter Journal: Lancet Date: 2010-11-04 Impact factor: 79.321
Authors: Kees J Kalisvaart; Jos F M de Jonghe; Marja J Bogaards; Ralph Vreeswijk; Toine C G Egberts; Bart J Burger; Piet Eikelenboom; Willem A van Gool Journal: J Am Geriatr Soc Date: 2005-10 Impact factor: 5.562
Authors: Elizabeth L Sampson; Peter R Raven; Patricia N Ndhlovu; Aaron Vallance; Nicholas Garlick; Julie Watts; Martin R Blanchard; Angela Bruce; Robert Blizard; Craig W Ritchie Journal: Int J Geriatr Psychiatry Date: 2007-04 Impact factor: 3.485
Authors: Dan K Kiely; Richard N Jones; Margaret A Bergmann; Katharine M Murphy; E John Orav; Edward R Marcantonio Journal: J Gerontol A Biol Sci Med Sci Date: 2006-02 Impact factor: 6.053
Authors: Tammy T Hshieh; Tamara G Fong; Edward R Marcantonio; Sharon K Inouye Journal: J Gerontol A Biol Sci Med Sci Date: 2008-07 Impact factor: 6.053
Authors: Tianjing Li; L Susan Wieland; Esther Oh; Karin J Neufeld; Nae-Yuh Wang; Kay Dickersin; Frederick E Sieber Journal: Clin Trials Date: 2017-01-09 Impact factor: 2.486
Authors: Shirley H Bush; Salmaan Kanji; José L Pereira; Daniel H J Davis; David C Currow; David Meagher; Kiran Rabheru; David Wright; Eduardo Bruera; Michael Hartwick; Pierre R Gagnon; Bruno Gagnon; William Breitbart; Laura Regnier; Peter G Lawlor Journal: J Pain Symptom Manage Date: 2014-01-28 Impact factor: 3.612